Tofacitinib versus etanercept or placebo in patients with moderate to severe chronic plaque psoriasis: patient‐reported outcomes from a Phase 3 study

Por Valenzuela, F., Paul, C., Mallbris, L., Tan, H., Papacharalambous, J., Valdez, H., Mamolo, C.
Publicado no J Eur Acad Dermatol Venereol (2016)

Effect of tofacitinib withdrawal and re‐treatment on patient‐reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis

Por Griffiths, C.E.M., Vender, R., Sofen, H., Kircik, L., Tan, H., Rottinghaus, S.T., Bachinsky, M., Mallbris, L., Mamolo, C.
Publicado no J Eur Acad Dermatol Venereol (2016)

Phase 3, open‐label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector...

Por Callis Duffin, K., Bagel, J., Bukhalo, M., Mercado Clement, I.J., Choi, S.L., Zhao, F., Gill, A., Pangallo, B., Shuler, C., Mallbris, L., Jackson, K.
Publicado no J Eur Acad Dermatol Venereol (2016)